Drugs / FENIRALSTAT
FENIRALSTAT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05118958 | May → Dec 2020 | hereditary angioedema | KalVista Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05178355 | Feb → Jun 2019 | hereditary angioedema | KalVista Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05055258 | Nov 2021 → Oct 2022 | hereditary angioedema | KalVista Pharmaceuticals, Ltd. | Terminated | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FENIRALSTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095064 ↗ |
| Known as | FENIRALSTAT HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095064 ↗ |
| Known as | KVD-824 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095064 ↗ |
| Known as | KVD824 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05178355 ↗ |
| Known as | KVD824.HCl | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095064 ↗ |
| Modality | Small molecule | — CHEMBL5095064 ↗ |
| Route | Oral | “an Oral Plasma Kallikrein Inhibitor” NCT05055258 ↗ |